Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -3.60 -2.95% 118.40 609,532 16:35:29
Bid Price Offer Price High Price Low Price Open Price
115.00 118.00 120.50 116.50 120.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.64 -21.34 -8.37 300
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:29 UT 3,767 118.40 GBX

Avacta (AVCT) Latest News

More Avacta News
Avacta Investors    Avacta Takeover Rumours

Avacta (AVCT) Discussions and Chat

Avacta Forums and Chat

Date Time Title Posts
25/10/202120:07Avacta – Innovative and Disruptive Technologies for Global Health Markets37,290
24/10/202110:27CV And The Deep State196
22/10/202101:51Covid-19. Ten Minute Test. Gamechanger!!67
11/10/202115:51avct The Fall!!!113
08/10/202122:51Covid-19. Ten Minute Test. Gamechanger!!19,481

Add a New Thread

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-10-25 15:35:29118.403,7674,460.13UT
2021-10-25 15:29:45117.505,1826,088.85O
2021-10-25 15:29:38117.50421494.68O
2021-10-25 15:29:25117.485,1025,993.83O
2021-10-25 15:29:07116.1622.32O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

Avacta Daily Update: Avacta Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 122p.
Avacta Group Plc has a 4 week average price of 104.50p and a 12 week average price of 97p.
The 1 year high share price is 290p while the 1 year low share price is currently 90p.
There are currently 253,236,345 shares in issue and the average daily traded volume is 1,298,237 shares. The market capitalisation of Avacta Group Plc is £299,831,832.48.
rajraj b: There are some on here who will be quite disappointed that the share price didn't crash on Friday (like they hoped for) and will now be looking for new angles to attack AVCT. I guess the main holders believe in the long term potential here and are not just solely waiting on LFT results. Of course there will be a fair few who are only interested in the LFT but, judging by the share action on Friday, even they still feel confident that this will be delivered in the short term by AVCT. Anyway, good luck to all those who remain firm. Those who are looking for new angles, don't bother! PWhite has managed to save those souls who wished to be parted from their shares. I wonder how many of them were convinced to sell when the share price was bellow 109 recently?
pwhite73: Lostabillion - No update about AVA6000 will result in any sustained rise in the share price. AVA6000 is still at Phase I. There is no commercial value at this stage. Matters only become serious for oncology drugs at Phase II/III. AVCT are working on a cure for cancer. Cancer cells can easily be killed by many methods including drinking a bottle of weed killer. The problem with all cancer treatments is that they destroy healthy cells even when successful. If AVA6000 can allow drugs like doxorubicin to destroy cancer cells whilst protecting healthy cells then that is the cure for cancer. That is the cure that has eluded the world's major pharmaceutical companies for decades and has cost them trillions. What you need to look out for are papers published in medical journals by AVCT about the progress they are making on AVA6000. If all you're getting is RNS statements written by the nomad then forget it. That is the main difference between pharma companies that are genuinely working on cancer therapies and those that are not. They publish the progress of their work in medical journals to be reviewed by their peers all over the world. Indeed that is a requirement by the FDA that your research work is published so global pharmas, hospitals, scientists can challenge your findings.
pwhite73: viking24 - "Avacta can be added any time." That's right and that's why the share price has halved from 280p. Anytime can be tomorrow or 22/10/2022. You need anytime to be now if the share price is to hold.
pwhite73: deme1 - I'm not sure you fully appreciate what the delay is and why AVCT hasn't been approved already. All the approved test providers are using reagents/antibodies (this is a stipulation by the government) to determine to what extent someone is infected with the virus. Their PCR machines are also using reagents/antibodies. What adaptions will be needed to use affimers that are unique only to AVCT. AS has already advised the market is crowded with LFTs so will HUA generate any additional sales for AVCT. If you check out the list of existing approved test providers they advise which LFTs they are using. For AVCT to break into this market existing contracts will need to be terminated and AS has already stated the AVCT LFT is one of the more expensive due to its higher quality. Any announcement of HUA approval may cause a small rise in the share price but its not going to last long. You need to think seriously about your investment here.
pwhite73: lith - Any BB can weather the deramping storm if the share price is rising, it gives the longs something to counter with and proves them right. When the share price has collapsed more than 50% its a losing battle.
pwhite73: grosstonnage - "I’m seeing these low prices as an opportunity to add to my holding" These prices are not low. Read the two statements made buy David Budd of GDR and look at the difference between the two share prices. David Budd CEO Genedrive 22/05/2020 Share price 235p - "The development teams at genedrive and at Cytiva have worked tirelessly over the past 2 months to develop our unique product that has the potential to streamline lab testing, improve quality, and ultimately allow more people to be tested. CE marking was achieved with performance studies and validations that will also support regulatory applications in other jurisdictions, such as Emergency Use Authorisation with the USA FDA and Emergency" David Budd CEO Genedrive 29/09/2021 Share price 25p - "Our thanks go to the shareholders that have participated in this Open Offer, which has resulted in a further GBP1.1 million of gross proceeds being raised. The net proceeds of the Fundraising will allow us to further fund our Genedrive(R) COV19-ID Kit, support the commercial roll out of the AIHL test including new business development and additional product development, commercialisation efforts and general corporate costs.""
pwhite73: What's driving the price down is the widely held belief among institutions and private investors that AVCT cannot deliver on its Covid LFT project. It was this project that caused the share price to soar from 20p in April 2020 to 280p in May 2021. If the company still cannot gain any traction 13 months later then why is the share price still six times higher than 20p. With regards to manufacturing at GAD you cannot hide one million LFTs coming off the production line every month from August 2021. People gossip, workers at GAD would be using the LFTs themselves and it would be in the regional papers and online. I challenge you all to find a single story anywhere of Covid LFTs currently being manufactured at Thurleigh Bedfordshire. Speak Later
tickboo: - AVCT LFT has market leading performance - significant commercial opportunity remains- UK manufax capacity 2 - 3m per month, can be scaled in UK and abroad- Commercial traction is building- "Extremely pleased" to have achieved goal of bringing AVCT to clinical stage for its cancer therapies- IND filing for AVA6000 before the end of 2021 for P1 study in the US, "confident we will achieve that"- Strong balance sheet - support core business and working capital for Covid testing opportunityQuestionsHow are you following PKP and toxicology of AVA6000? Measuring levels of dox in plasma and urine - straightforward way to do that in 72 hours post-dose and measure how they are eliminated by the bodyWhen will shareholders be given indication of how AVA6000 is going?Positive guidance today, totally inappropriate to talk about data today as there is only a single patient currently having been dosed, but we are very pleased with progress - new sites and new patients in trial soon, no concern re: scheduling, we will update the market as soon as we possibly can, escalating dose and starting next cohort is strong indicator that regulators are happy with safetyWhen is HUA expected for LFT, and any clarity on why the process has taken so long?Additional lay user study focuses on usability rather than clinical validation, this is combined with technical data for test performance, full technical file submitted for review - M19 have led this process and done an outstanding job - taken a long time but notifiable body review can take many months even under 'normal times' - 'sincerely hope' we are close but it's out of our handsWhy has there seemingly been no commercial interest in LFT?This is just not true to say there has been no commercial interest, we are clearly not the first test to market but we are an extremely good test, will take time to build market share, business development, marketing, approvals in new territories and potentially licensing. Covid testing will be around for years, seasonal element and risk of new variants. This is a long term commercial opportunity and we will build on itComment on significant share price decline and how you will address it?Falling share price clearly not desirable, however AS remains focused on driving business forward, which means a profitable diagnostics division and unlocking value in therapeutics initially via success of AVA6000 - this will unlock a further 'incredible' pipeline. Potential value of Precision platform working well in humans and enhancing the effects of chemo 'dwarves' the value of Covid testing
pwhite73: dalep176 - The direction of the share price correctly reflects what's going on. The share price and market cap rocketed as the company leveraged its products to cash in on the Covid bonanza. For political and technological reasons it has not been able to commercialise its Covid projects. The share price is receding from whence it came. It should be reflecting only the AVA6000 phase 1 trials and what little revenue is obtained from the Affimers. I said a while back that clinical trials in the UK carry no commercial or scientific weight with the US. I note the company has now decided to make an application to initiate AVA6000 Phase I trials in the US. It will need to do this if US money and US companies are to climb on board. It is a step in the right direction but commercially the Phase I trials have technically been put back one year.
blackvulture: The dilution doesn't matter if the CEO is looking after the share price. That's what's important to small shareholders. Not the market cap or the number of shares in issue but the share price. Brad was looking after the share price that's the sole reason why I bought in without any business to speak of. That's the difference between the new team and the old. The old team drove the share price down from 0.40p to 0.006p whilst paying themselves £200k p.a each. They cared not one iota and to this very day still don't as their recent actions to destroy what's left of ICON proves.
Avacta share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211026 04:53:39